Long-term cross-sex hormone therapy for transgender individuals is associated with potential cardiovascular risks, but psychological benefits, according to a review published in Annals of Internal Medicine.
The investigators call for more research to determine the cardiovascular risk factors in gender affirming care.
Heart in Diabetes
This activity is supported by educational funding provided by Amgen, Novartis Pharmaceuticals Corporation and St. Jude Medical, Inc.
This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc. Endorsed by: The National Lipid Association.
This educational activity is supported by an educational grant from Quest Diagnostics, Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
©2017 Healio All Rights Reserved.